Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Generate Biomedicines, Maintains $30 Price Target

Oct 5, 2026, 10:38 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Generate Biomedicines (NASDAQ:GENB) with a Buy and maintains $30 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncOct 16, 2026, 2:00 PMTowards Healthcare
Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR. India's pharmaceutical market recorded 17.1% year-over-year growth in September 2026. Key growth drivers include biologics, AI-driven drug discovery, specialty medicines, and manufacturing investments. Asia Pacific is expected to grow faster than the global average at 7.02% CAGR, while North America maintains 36% market share.
ZLDPY GENB
BenzingaOct 14, 2026, 3:30 PMVandana Singh
Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market
Generate Biomedicines & Zealand Pharma team up to develop AI-engineered protein therapies for obesity & metabolic diseases.
GENB
BenzingaOct 13, 2026, 8:34 PMBenzinga Newsdesk
Generate Biomedicines To Receive $30M Upfront, Up To $1.2B In Milestones And Tiered Royalties Under Zealand Pharma Collaboration
Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a multi-target strategic collaboration with Zealand Pharma A/S (NASDAQ:ZEAL), a biotechnology company transforming the future of metabolic
GENB ZEAL
BenzingaOct 13, 2026, 8:15 PMBenzinga Newsdesk
'Zealand Pharma Makes Deal With Generate Worth Up to $1.2 Billion' - Bloomberg
GENB